Gsk Plc ADR (GSK)
$38.94
0.45 (1.14%)
GSK Stock Quote Delayed 30 Minutes
Hard-to-Find Bargain Stock Buys
The stock market's brisk fourth-quarter rally (which has since begun to stall) has made bargains more difficult to find, but here's a few.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
209.70B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.40M
Day's Range
$38.80 - $39.27
52-Week Range
$33.67 - $45.92
Dividend & Yield
$1.44 (3.71%)
GSK Stock Predictions, Articles, and Gsk Plc ADR News
Onyx Pharma May See Suitors Lining Up
The company's current and future drugs are likely attractive to larger companies faced with slowing growth.
Stocks to Watch on Cancer Vaccines’ Huge Financial Potential
These companies are making progress on new therapeutic cancer vaccines -- and success for any one of them could be huge for investors.
Big Pharma’s Emerging Markets Foray Hits Roadblocks
Companies are finding plans for global expansion aren't without hiccups.
Take the Cure — Sell J&J, Buy GSK
Johnson & Johnson and GlaxoSmithKline both have solid balance sheets, but GSK is poised to outperform its competitor.
Should You Buy the Dow — Pfizer
Pfizer's financials are decent, as is its lineup of drugs and personal care products, but the stock is fully valued.
Should You Buy the Dow — Merck
Merck is a strong, old company with a good dividend -- it suits retirement accounts fine, but regular traders might want to keep their distance.
Is Abbott’s Spinoff the Beginning of a Trend?
A look at Abbott Labs' (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies.
Pfizer Crafting a Post-Patent Game Plan
As its Lipitor patent nears expiration, Pfizer considers new uses for Lyrica, its popular painkiller for fibromyalgia.
Glaxo Alters R&D Process to Ensure Survival in Changing Pharma Industry
GSK has created a "dragon" culture in its R&D process. Here's what it is and why analysts like the Glaxo approach.
Tiny Amarin Banking on Fish Oil Drug Success
The stock's upside is potentially huge if this drug takes off.
Big Pharma Eyes Rare-Disease Revenue Stream
Large drug firms are starting to look beyond common maladies to keep the cash coming.
In Event of Bird Flu Pandemic, Vaccine Producers Likeliest to Prosper
A mutant strain of H5N1 could be spreading in Asia, meaning vaccine heavyweights might be going back to the drawing board.
Gilead Aims to Duplicate HIV Success With Combo Cancer Drugs
Analysts mostly positive about GILD's future, and even the company's current numbers are up to snuff.
Big Pharma Banking on New Cancer Treatment Approach to Boost Sales
GlaxoSmithKline, Eli Lilly and Novartis are among the companies studying epigenetics -- a new approach to fighting cancer that is already seeing some success.
Allergan’s Good Looks May Be Too Pricey
Expected uptick in breast implants, wrinkle fillers is good news for Botox creator, but many investors think AGN still costs too much.
Is Big Pharma Resistant to Antibiotics?
Less profitable drugs take a backseat despite health risks
Big Pharma Stocks Have Big Challenges Ahead
Tougher FDA approvals and expiring patents mean good times for Big Pharma could be fleeting, but a few stocks are worth striking at while the iron's hot.
7 Health Care Stocks to Sell
Big pharma is in big trouble, with looming patent expirations and drug generic competition weighing on drug related stocks.
